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1 Abstract 24 
The Na+/glucose cotransporter 1, SGLT1 is the major route for transport of dietary glucose from the 25 
lumen of the intestine into absorptive enterocytes. Sensing of dietary sugars and artificial sweeteners 26 
by the sweet taste receptor, T1R2-T1R3, expressed in the enteroendocrine L-cell regulates SGLT1 27 
expression in neighboring absorptive enterocytes. However, the mechanism by which sugar sensing 28 
by the enteroendocrine cell is communicated to the absorptive enterocytes is not known. Here, we 29 
show that glucagon-like peptide-2 (GLP-2) secreted from the enteroendocrine cell in response to 30 
luminal sugars regulates SGLT1 mRNA and protein expression in absorptive enterocytes, via the 31 
enteric neurons. Glucose and artificial sweeteners induced secretion of GLP-2 from mouse small 32 
intestine, which was inhibited by the sweet-taste receptor inhibitor, gurmarin. In wild type mice there 33 
was an increase in sugar-induced SGLT1 mRNA and protein abundance that was not observed in 34 
GLP-2 receptor knockout mice. GLP-2 receptor is expressed in enteric neurons, and not in absorptive 35 
enterocytes ruling out a paracrine effect of GLP-2. Electric field stimulation of the intestine resulted 36 
in upregulation of SGLT1 expression that was abolished by the nerve blocking agent tetrodotoxin. 37 
We conclude that GLP-2 and the enteric nervous system are components of the enteroendocrine-38 
absorptive enterocyte communication pathway regulating intestinal glucose transport.  39 
 40 
2 Introduction 41 
The Na+/glucose cotransporter 1, is expressed on the brush border membrane of absorptive 42 
enterocytes, and is the major route for transport of dietary glucose across the lumen of the intestine 43 
(1,2). Absorption of glucose via SGLT1 is maximal in proximal small intestine. It has been long 44 
recognized that the activity and expression of SGLT1 is upregulated in response to increased intake 45 
of dietary carbohydrates or luminal monosaccharides (3,4). The gut epithelium can sense luminal 46 
sugars and artificial sweetens via the G-protein coupled sweet taste receptor, T1R2-T1R3, expressed 47 
in enteroendocrine cells to modulate its Na+- dependent glucose absorptive capacity (5-7). Short-term 48 
intravenous or serosal administration of GLP-2 leads to an increase in the expression of SGLT1, 49 
maximal rate of Na+-dependent glucose transport and an associated enhancement in blood glucose 50 
concentration (8-11). Moreover, increased levels of intracellular cAMP in absorptive enterocytes 51 
augment SGLT1 expression by enhancing the half-life of SGLT1 mRNA (12,13), suggesting the 52 
involvement of this second messenger in the SGLT1 regulatory pathway. However, the complete 53 
endocrine cell-absorptive enterocyte communication pathway regulating intestinal Na+/glucose 54 
cotransport is not known. 55 
Expression and activity of SGLT1 are significantly increased in the intestine of patients with type 2 56 
diabetes (14) and obesity (15-16). However, the reason for this remains unknown. Elucidating the 57 
pathway underlying regulation of SGLT1 will further our understanding of deregulation of this 58 
process in pathology. In this study our goal was to determine the mechanism by which 59 
enteroendocrine sensing of sugar regulates glucose absorptive capacity of absorptive enterocytes, and 60 
to investigate the possible role of GLP-2 in this process. Considering that the GLP-2 receptor is 61 
expressed in enteric neurons, and not in absorptive enterocytes (17,18), we present several lines of 62 
evidence to demonstrate that GLP-2 regulates SGLT1 mRNA and protein abundance in absorptive 63 
enterocytes via a neuro-paracrine pathway. Moreover, we show that the GLP-2 dependent pathway 64 
underlying regulation of SGLT1 expression is distinct from GLP-2 induced intestinal growth. 65 
 66 
3 Materials and methods 67 
3.1 Reagents 68 
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All reagents were obtained from Sigma Aldrich (Poole, Dorset, UK) or Fisher Scientific 69 
(Loughborough, UK). 8-bromo- cAMP (8-Br-cAMP, B5386, Sigma) was prepared fresh immediately 70 
before use. Pituitary adenylate cyclase-activating polypeptide-38 (PACAP, A1439, Sigma), the 71 
dominant peptide in all tissues examined, was used in these experiments. Vasoactive intestinal 72 
peptide (VIP,V6130, Sigma), PACAP, corticotrophin-releasing hormone (CRH, C3042, Sigma) and 73 
calcitonin gene-related peptide (CGRP, C0168, Sigma) were dissolved in 175 mM acetic acid and 74 
substance P (S6883, Sigma) in 50 mM acetic acid with 1% (w/v) bovine serum albumin (A8806, 75 
Sigma). Tetrodotoxin (TTX, NA-120, Enzo Life Sciences, Exeter, UK), dissolved at 1 mg/ml in 1% 76 
(v/v) acetic acid, was stored at –20°C and thawed immediately before use.  Peptides were stored in 77 
aliquots at –80°C and defrosted immediately before use.  78 
 79 
3.2 Mice, diets and tissue collection 80 
The generation of the C57BL/6 Glp2r-/- mice has been reported previously (19). Two male and 2 81 
female Glp2r+/- mice were obtained from Dr. Drucker’s laboratory, Toronto, Ontario. They were bred 82 
at the licensed breeding facilities at the University of Liverpool Biomedical Services Unit, to produce 83 
GLP-2 receptor knockout (Glp2r-/-) mice and wild type offspring. Both male and female mice aged 84 
between 8 and 10 weeks were used for assessing the effect of GLP-2 receptor deletion on 85 
carbohydrate-induced regulation of SGLT1 expression. For all other experiments, male C57BL/6 86 
mice, aged 8 week, purchased from Charles River Laboratories (Margate, Kent, UK), were utilized. 87 
All mice had access to water and food and were housed in standard tube cages with automatically 88 
controlled temperature and humidity and a 12:12 h light-dark cycle. The amount of daily food intake 89 
was similar across diets and genotype (Table S1).  All mice were killed by cervical dislocation in 90 
accordance with the UK Animals (Scientific Procedures) Act, 1986 and with guidelines set out by the 91 
University of Liverpool Ethics Committee and in line with UK Home Office schedule 1 regulations. 92 
Depending on the experiment, mice were maintained either on a 40% carbohydrate (CHO)-93 
containing diet (Testdiet #5755, energy 3.70 kcal/g, Purina Mills, Richmond, IN), or standard chow 94 
(61.8% CHO, energy 3.60 kcal/g; Special Diet Services, Witham, Essex, UK) . Mice used for 95 
low/high-CHO feeding were initially kept on the 40% CHO-containing diet before switching to 96 
either a low-CHO (1.9% CHO, Testdiet #590N, energy 3.86 kcal/g,) or a high-CHO diet (69.9% 97 
CHO, Testdiet #5810, energy 3.77 kcal/g). We have previously demonstrated that SGLT1 expression 98 
is upregulated when the CHO (sucrose) content of the diet exceeds 50% (7,20). The 5-day feeding 99 
period was selected to cover intestinal turnover from crypt to villus taking place 4-5 days (21) and 1 100 
day dietary trial was chosen to determine if any increase occurs in existing enterocytes. All diets were 101 
isocaloric. To consider the influence of circadian periodicity on SGLT1 expression (22), mice were 102 
always killed at 10 am and diets were switched at selected times to ensure that the period of low/high 103 
CHO feeding always terminated at 10 am. Immediately after sacrifice, the entire small intestine was 104 
removed and the lumen flushed with ice cold 0.9% (w/v) saline and separated into three equal regions 105 
designated proximal, mid and distal. Sections of tissue (1 cm) from the proximal part of each region 106 
were fixed for immunohistochemical determinations, or frozen in liquid nitrogen for RNA analysis, 107 
with the remaining intestinal tissue being used for brush border membrane vesicle (BBMV) 108 
preparations. Tissue (1-2 cm) from C57BL/6 wild-type mice, maintained on chow, was flushed with 109 
saline, opened longitudinally and serosa removed by gentle scrapping as reported previously (23). 110 
These freshly prepared tissues were employed for gut hormone secretion assays. Hematoxylin (H) 111 
and eosin (E) staining confirmed the intactness of the villi with the serosa removed. Proximal 112 
intestine, from C57BL/6 wild-type mice maintained on the 40% CHO-containing diet, were used for 113 
electrical field stimulation studies.  114 
 115 
3.3 Preparation of brush-border membrane vesicles  116 
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Brush border membrane vesicles (BBMV) were isolated from intestinal tissues based on the 117 
procedure described by Shirazi-Beechey et al. (24) with modifications outlined by Dyer et al. (5). All 118 
steps were carried out at 4°C. Tissues were thawed in a buffer solution (100 mM mannitol, 2 mM 119 
HEPES/Tris pH 7.1 (BP310, Fisher) with protease inhibitors, 0.5 mM dithiothreitol (D9779, Sigma), 120 
0.2 mM benzamidine (B6506, Sigma), and 0.2 mM phenolmethylsulfonyl fluoride (P7626,Sigma)), 121 
cut into small pieces and vibrated for 1 min at speed 5 using a FUNDAMIX vibro-mixer (DrM, Dr 122 
Mueller AG, Maennedorf, Switzerland) in order to free epithelial cells. Subsequently, the suspension 123 
was filtered through a Büchner funnel to remove any muscle and connective tissues. The filtrate was 124 
then homogenized using a Polytron (Ystral, Reading, Berkshire, UK) for 30 s at speed 5. Next, 125 
MgCl2 was added to the resulting homogenate to a final concentration of 10 mM and the solution 126 
stirred on ice for 20 min. The suspension was then centrifuged for 10 min at 3,000 x g (SS34 rotor, 127 
Sorvell, UK) and the resulting supernatant was spun for 30 min at 30,000 x g. The pellet was 128 
suspended in buffer (100 mM mannitol, 0.1 mM MgSO4, and 20 mM HEPES/Tris pH 7.1) and 129 
homogenized with 10 strokes of a Potter Elvehjem Teflon hand-held homogenizer before 130 
centrifuging for 30 min at 30,000 x g. The final pellet was re-suspended in an isotonic buffer solution 131 
(buffer 3, 300 mM mannitol, 0.1 mM MgSO4, and 20 mM HEPES/Tris pH 7.4) and homogenized by 132 
passing through a 27-gauge needle several times. The protein concentration in the BBMV was 133 
estimated by its ability to bind Coomassie blue according to the Bio-Rad assay technique (Bio-Rad, 134 
Hemel Hempstead, UK). Porcine γ-globulin (G-2512, Sigma) was used as the standard. In 135 
preparation for western blot analysis, aliquots of freshly prepared BBMV were diluted with sample 136 
buffer (62.5 mM Tris/HCl pH 6.8, 10% [v/v] glycerol, 2% [w/v] SDS, 0.05% [v/v] β-mercaptoethanol 137 
(M-7154, Sigma), 0.05% [w/v] bromophenol blue (035730, BDH)) and stored at -20°C until use. The 138 
remaining BBMV were either diluted 1:100 in buffer 3 and stored at -20oC for enzyme activity 139 
determination or were used immediately for glucose uptake studies. 140 
 141 
3.4 Immunohistochemistry 142 
Mouse small intestinal tissues, removed from control and Glp2r-/- mice and used for single or triple 143 
immunohistochemistry were processed following protocols published previously (7,20). Small 144 
intestinal sheets were fixed for 4 hour in 4% paraformaldehyde (P/0840/53, Fisher) and then placed 145 
in 20% (w/v) sucrose (84100, Fluka, Gillingham, Dorset, UK) in PBS overnight. Subsequently, tissue 146 
samples were gelatin embedded [7.5% (w/v) gelatin G1890, Sigma, 15% (w/v) sucrose] and frozen in 147 
liquid nitrogen cooled isopentane and then kept at -80°C until use. Tissue sections (10 µm thick) 148 
were sectioned on a cryostat (Leica, CM 1900UV-1-1, Milton Keynes, Buckinghamshire, UK), thaw 149 
mounted onto polylysine coated slides and washed five times for 5 minutes each in PBS. Slides were 150 
then incubated for 1 hour in blocking solution. For procedures using antibodies to T1R2 and T1R3 151 
the blocking solution consisted of 5% (w/v) sucrose, 3% (w/v) bovine serum albumin (A9647, 152 
Sigma), 2% (v/v) donkey serum and 0·1% (w/v) sodium azide in PBS, whereas the blocking solution 153 
for procedures using antibodies to VPAC1, VPAC2 (VIP/PACAP receptors 1 & 2) and GLP-2, 154 
consisted of 3% (w/v) bovine serum albumin, 2% (v/v) donkey serum and 0·1% (w/v) sodium azide in 155 
PBS. Tissues were incubated at 4°C overnight with primary antibodies. Antibodies to T1R2 (1:750, 156 
sc-22456), T1R3 (1:750, sc-50353), GLP-2 (1:100, sc-7781), VPAC1 (1:100, sc-15958) and VPAC2 157 
(1:100, sc-15961), were purchased from Santa Cruz Biotechnology, INC., Santa Cruz, CA, USA. The 158 
composition of the buffer containing antibodies (primary and secondary) was 2.5% (v/v) donkey 159 
serum, 0.25% (w/v) NaN3 and 0.2% (v/v) triton X-100 (H5141, Sigma) in PBS. For triple 160 
immunohistochemistry, two serial tissue sections were incubated with primary antibodies. One 161 
section was incubated with two primary antibodies raised in different species whilst the adjacent 162 
section was incubated with the third primary antibody. Following incubation with primary antibodies, 163 
slides were washed with PBS before incubating with secondary antibodies.  Secondary antibodies  164 
were either cyanine 3-conjugated anti-goat (705-165-147) or anti-rabbit (711-165-152), raised in 165 
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donkey,  fluorescein isothiocyanate-conjugated anti-rabbit raised in donkey (711-095-152) purchased 166 
from Stratech Scientific Ltd (Suffolk, UK), or cyanine 3-conjugated anti-mouse raised in donkey or 167 
goat (715-165-151, Jacksons ImmunoResearch Europe Ltd, Cambridge, UK). All secondary 168 
antibodies were used at a dilution of 1:500. Finally, the slides were washed with PBS three times for 169 
5 min and mounted in Vectashield hard set mounting media with DAPI (H-1500, Vector 170 
Laboratories, Burlington, CA, USA). The immunostaining was visualized using an epifluorescence 171 
microscope (Nikon, UK) and images were captured with a Hamamatsu digital camera (C4742-95). 172 
Images were merged using Imaging Products Laboratory software (BioVision Technologies, Exton, 173 
PA, USA).  174 
 175 
3.5 Gut hormone secretion studies 176 
Segments of mouse intestine (~2cm) were prepared and treated as previously described (25). Briefly, 177 
freshly removed 2 cm segments, with the serosa removed, were incubated at 37°C, 5% CO2, in 178 
incubation media [500 µl, Dulbecco’s modified Eagle’s medium (5.55 mM glucose, D5546, Sigma) 179 
with 10% (v/v) Fetal Bovine Serum (FBS, EU-000-F, Sera Labs International, UK), 2 mM L-180 
glutamine (G7513, Sigma), 100 U/ml penicillin/ 100 µg/ml streptomycin (P0781, Sigma), 20 µl/ml 181 
dipeptidyl peptidase IV inhibitor (DPP4-010, Millipore)], gassed with Carbogen (95% CO2, 5% O2) 182 
and supplemented with appropriate concentrations of test agents: 10-200 mM D-glucose (10117, 183 
VWR, Leicestershire, UK), mannitol (M9647, Sigma), or artificial sweetener (10 mM, gift from 184 
Pancosma, SA, Switzerland). Control tissues were maintained simultaneously in incubation media. 185 
For treatments with gurmarin (the inhibitor of rodent T1R3) (26), tissues were first pre-incubated 186 
with 5 µg/ml gurmarin as determined before (23,25) for 30 min followed by incubation in media 187 
containing both gurmarin and test agents. After 1 h, incubation media were collected, centrifuged to 188 
remove cell debris, and stored at –80°C. Secretion of GLP-2 was determined using a commercial 189 
enzyme immunoassay kit (EK-028-14, Phoenix Pharmaceuticals, Phoenix Europe GmbH, Karlsruhe, 190 
Germany), following the manufacturers’ instructions. The measurements were within the linear part 191 
of the standard curve. 192 
In order to ensure that GLP-2 secretion was not biased by L-cell distribution along the length of the 193 
small intestine, parallel longitudinal gut sections for individual mice were used for each test 194 
condition. Cellular and tissue integrity were assessed histologically and by measuring the levels of 195 
lactate dehydrogenase, a cytoplasmic marker, as described previously (23). Standard curves were 196 
constructed using GraphPad Prism 5 (GraphPad Software).  197 
 198 
3.6 Electrical field stimulation (EFS) 199 
This procedure was used as described previously (27), with modifications designed for stimulating 200 
enteric neurons. Freshly removed intact mouse proximal intestinal tissues maintained in oxygenated 201 
(Carbogen) Krebs-Henseleit buffer (110 mM NaCl (S/3160/65, Fisher), 4.7 mM KCl (P/4280/60, 202 
Fisher), 3 mM CaCl2 (C3306, Sigma), 1.2 mM MgCl2, 25 mM NaHCO2 (10247, VWR), 1.15 mM 203 
NaH2PO4 (10245, VWR), 5.55 mM D-glucose, 4.9 mM NaPyruvate (P5280, Sigma), 2.7 mM 204 
NaFumarate (F1506, Sigma), 4.9 mM NaGlutamate (G1626, Sigma)) at 37 °C were flushed with 205 
Krebs-Henseleit buffer and divided into 3 cm loops. Each loop was tied at one end with a weight 206 
attached in order for the tissue to be kept vertical. The tissue was then placed into a tissue bath 207 
containing 10 ml of Krebs-Henseleit buffer, fitted with a water jacket maintained at 37°C. Tissues 208 
were allowed to equilibrate in the bath for 20 min. Electric stimulation of the tissue was achieved 209 
using 0.5 mm diameter platinum wire electrodes, with one electrode placed inside the intestinal loop 210 
at ~3 mm to the luminal membrane and the other outside the loop at the same distance. Electrical 211 
current was applied using square wave pulses employing a Grass S44 stimulator (Natus Neurology 212 
Incorporated, Grass Products, Warwick PI, USA). The frequency was 20 Hz with duration of 0.3 ms, 213 
and delay of 1 ms using a voltage of 50 V (5 mA, measured using Keithley 6485 Instruments, 214 
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Tektronix UL Ltd. Berkshire, UK). Three sets of tissue loops were used per experiment. The tissue 215 
loops which were not stimulated served as controls. One set of tissue loops that did receive EFS were 216 
preincubated with 10 µM TTX for 15 min before stimulation in TTX-containing buffer. Immediately 217 
following EFS a small section of tissue (0.5 cm) was used for mRNA isolation and the remainder of 218 
the tissue for BBMV preparation. In all three sets of tissues, control and stimulated ± TTX, 219 
immunohistochemistry showed that tissue integrity was retained and that SGLT1 expression had a 220 
similar profile; being expressed on the luminal membrane of villus enterocytes with no expression in 221 
the crypt as shown before (20, 25,28) (data not shown). 222 
 223 
3.7 Cell culture 224 
The small intestinal enterocytic cell line Caco-2/TC7 (Caco-2) cells were maintained at 37 °C and 225 
5% CO2 in Dulbecco’s modified Eagles’ medium (D6546, Sigma), supplemented with 10% (v/v) 226 
fetal bovine serum, 1% (v/v) non-essential amino acid solution (M7145, Sigma), L-glutamine (2 227 
mM), and penicillin/streptomycin (100 U/ml; 100 µg/ml) (basal medium). Six well plates were 228 
seeded with Caco-2 cells at 100,000 cells/cm2 and grown to confluency (approx. 7 d) before being 229 
incubated in media containing either 0.5 mM 8-Br-cAMP, as described before (5) or a range of 230 
concentrations of VIP, PACAP, CRH, CGRP or Substance P. Control wells were treated with basal 231 
medium only. Equal amounts of solvents, acetic acid or acetic acid with 1% (w/v) bovine serum 232 
albumin, were included in corresponding control media. The time course of the response was 233 
determined to establish that 24 h incubation period was the shortest period to give a reliable and 234 
significant difference in SGLT1 expression (data not shown) Cells were harvested after 24 h. Cell 235 
pellets were collected after centrifugation and frozen at –80°C until used (see Table S2 for primer 236 
sequences).  237 
 238 
3.8 Preparation of post nuclear membranes  239 
Post nuclear membranes (PNM) were isolated as described previously (23). Caco-2 cells grown as 240 
described above (under 3.7 cell culture) were harvested and cell pellets were collected after 241 
centrifugation and frozen at –80°C until used. Caco-2 cell pellets were thawed in buffer (100 mM 242 
mannitol, 2 mM HEPES/Tris pH 7.1, 50X complete protease inhibitor cocktail (11836145001, Roche, 243 
Sigma)) and homogenized using a Polytron (10 s on setting 5) and centrifuged at 1000g for 10 244 
minutes at 4°C, using a swing-out rotor (HB6, Sovall). The resulting supernatant was centrifuged at 245 
30,000g for 30 minutes at 4°C with the resulting pellet re-suspended in 0.5 ml buffer and transferred 246 
to a sterile Eppendorf tube and centrifuged at 30,000g for 30 minutes at 4°C. The PNM pellet was re-247 
suspended in a buffer consisting of 300 mM mannitol, 20 mM Hepes/tris pH 7.4, 0.1 mM MgSO4 and 248 
homogenized by passing through a 27G needle several times. 249 
 250 
3.9 Western blotting 251 
BBMV were prepared as previously described (24). The abundance of SGLT1 protein in BBMV was 252 
determined by western blotting using our well characterized antibody to SGLT1 (5,7,20,29). The 253 
antibody to SGLT1 was raised in rabbits (custom synthesis) to a recombinant protein corresponding 254 
to amino acids 554-640 of rabbit SGLT1, sharing 81.6% homology to the murine SGLT1 sequence. 255 
Protein components of BBMV and PNM were separated by SDS-polyacrylamide gel electrophoresis 256 
on 8% (w/v) polyacrylamide mini gels, containing 0.1% (w/v) SDS, and electrotransferred to PVDF 257 
membrane (1620264, Immun-Blot, Bio-Rad Laboratories Ltd. Hemel Hempstead, UK). Membranes 258 
were blocked by incubating for 1 h at room temperature in PBS-TM buffer (PBS containing 0.5% 259 
(w/v) non-fat dried milk (LP0031,Oxoid, UK), and 0.1% [v/v] Tween-20 (20605, Fisher) before 260 
incubation with SGLT1 antibody diluted 1:5000 in PBS-TM. For the determination of SGLT1 261 
protein abundance in PNM, blocking with 5% (w/v) milk and an overnight incubation at 4°C were 262 
used. Immuno-reactive bands were detected by incubation for 1 h with affinity purified horseradish 263 
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peroxidase-linked anti-rabbit secondary antibody (P0217, DAKO Ltd, Cambridge, UK) diluted 264 
1:2000 in PBS-TM. Protein bands were visualized with WEST-one™ western blot detection system 265 
(16031, iNtRON Biotechnology, Chembio Ltd, Hertfordshire, UK) and Bio-Max Light 266 
Chemiluminescence Film (Z373508, Sigma). Scanning densitometry was performed using Total Lab 267 
(TotalLab, Newcastle-upon-Tyne, UK). Membranes were stripped by 3 x 10 min washes in 137 mM 268 
NaCl, 20 mM glycine/HCl (pH 2.5)  and re-probed with a monoclonal antibody to β-actin (clone AC-269 
15, Sigma Aldrich) used as loading controls. Blocking solution consisted of 5% (w/v) skimmed milk 270 
powder in PBS-TE (PBS, 0.1% (v/v) Triton X-100, 0.1 mM EDTA). Incubation and washing buffers 271 
were also PBS-TE. Horseradish peroxidase-linked anti-rabbit secondary antibody (P0447, DAKO 272 
Ltd) diluted 1:2000 in PBS-TE was used, and visualized as above. 273 
 274 
3.10 Measurement of Na+-dependent glucose uptake in BBMV  275 
Na+-dependent glucose uptake into BBMV was measured as previously described (20,29). The 276 
uptake of D-glucose was initiated by the addition of 100 µl of incubation medium (100 mM NaSCN 277 
[or KSCN], 100 mM mannitol, 20 mM HEPES/Tris [pH 7.4], 0.1 mM MgSO4, 0.02% [w/v] NaN3 and 278 
0.1 mM [U-14C]-D-glucose [10.6 GBq/mmol, NEC043X001MC, Perkin Elmer, Seer Green, Bucks, 279 
UK]) to BBMV (100 µg protein) at 37°C. The reaction was stopped after 3 s by the addition of 1 ml 280 
of an iso-osmolar ice-cold stop buffer (150 mM KCl 20 mM HEPES/Tris [pH 7.4], 0.1 mM MgSO4, 281 
0.02% [w/v] NaN3 and 0.1 mM phloridzin (274313, Sigma). Aliquots (0.9 ml) of the reaction mixture 282 
were removed and filtered under vacuum through a 0.22 µm pore cellulose acetate/nitrate filter 283 
(GSTF02500, Millipore, Hertfordshire, UK). The filter was washed with 5 x 1 ml of ice-cold stop 284 
buffer, placed in a vial containing 4 ml of scintillation fluid (Scintisafe 3, SC/9205/21, Fisher 285 
Scientific, UK) and the radioactivity retained on the filter was measured using a Tri-Carb 2910TR 286 
Liquid Scintillation Analyzer (PerkinElmer, Bucks, UK). All uptakes were measured in triplicate. 287 
Suitable substrate concentration, and kinetic parameters of glucose uptake were assessed previously 288 
and reported in our publications. Na+-dependent glucose uptake is determined by subtracting the 289 
glucose uptake in the presence of K+ from that of Na+. 290 
 291 
3.11 Morphometry 292 
Morphometric analysis was performed as previously described (20). 10 µm thick sections were 293 
exposed to tap water for 1 min, transferred to Mayer’s Haemalum (3.3 mM Mayer’s Haemalum-294 
haematoxylin, 1 mM sodium iodate, 0.42 mM potassium alum; mhs16, Sigma) for 1 min and washed 295 
gently with running tap water for 5 min. They were stained with eosin Y solution (1 % [w/v] eosin 296 
aqueous; hs250, HD Supplies, Buckingham, Bucks, UK) for 30 s and subsequently dehydrated by 297 
stepwise washing in 70% ethanol (v/v) for 2 x 1-min, absolute ethanol for 2 x 1-min, and xylene for 3 298 
x 1-min, before mounting with D.P.X. neutral mounting medium (317616, Sigma). 299 
Digital images were captured with an Eclipse E400 microscope and DXM 1200 digital camera 300 
(Nikon, Kingston upon Thames, Surrey, UK), analyzed using ImageJ software (Wayne Rasband, US 301 
National Institutes of Health, Bethesda, MD) and calibrated using a 100 μm gradient slide. The crypt 302 
depth and the villus height were measured as the average distance from crypt base to crypt-villus 303 
junction and villus base to villus tip, respectively. The villus height and the crypt depth 304 
measurements were taken from an average of sixteen well oriented crypt-villus units. A minimum of 305 
three images were captured per section at a minimum of 5 sections apart. All images were captured 306 
under the same conditions with care taken to ensure that the same villus was not counted twice.  307 
 308 
 309 
3.12 RNA isolation and quantitative real-time PCR (qPCR).  310 
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Expression of SGLT1 and VPAC1/2 mRNA was assessed by quantitative PCR as described before 311 
(23). RNA was isolated with the peqGOLD total RNA isolation kit with on-column DNase 1 312 
digestion, (12-6834-02, PEQLab, Hampshire, UK), and was used as template for first-strand cDNA 313 
synthesis using Superscript III reverse transcriptase (18080-044, Thermo Fisher, UK) and random 314 
hexamer primers (SO142, Fisher). cDNA was purified using QiaQuick PCR purification kit (28106, 315 
Qiagen, Crawley, UK) and qPCR assays were performed using 25 ng cDNA as template per 25 µl 316 
reaction containing SYBR Green JumpStart Taq ReadyMix for qPCR (S4438, Sigma Aldrich) and 317 
900 nM of each primer. PCR cycling was performed as follows: initial denaturation at 95°C for 2 min 318 
followed by 30-40 cycles of 95°C for 15 s, 60°C for 60 s in triplicate using a Rotorgene 3000 319 
(Qiagen, Crawley, UK). Relative abundance was calculated using RG-3000 comparative 320 
quantification software with RNA polymerase IIA (POLR2A) as control (see Table S2 for primer 321 
sequences). 322 
 323 
3.13 Statistics 324 
Commercial software (Graphpad Prism 5) was used for statistical analysis. D’Agostino & Pearson 325 
omnibus and Shapiro-Wilk normality tests were used to confirm that continuous variables were 326 
normally distributed. Comparison between groups was performed using Student’s unpaired t-test and 327 
one-way ANOVA as appropriate. Dunnett’s or Holm-Sidak’s multiple comparison post-test was used 328 
to determine differences between groups after identification of differences by ANOVA. The level of 329 
statistical significance was set at P < 0.05.  330 
 331 
4 Results 332 
4.1 Regulation of SGLT1 expression in wild-type (WT) and GLP-2 receptor knockout mice in 333 
response to dietary carbohydrate. 334 
Wild type and GLP-2 receptor knockout mice were kept on diets of different carbohydrate content as 335 
we described previously (7) for 5 days before measuring intestinal expression of SGLT1. In wild type 336 
mice kept on a high- carbohydrate (70% sucrose) diet, SGLT1 mRNA abundance was 2.1- fold 337 
higher (P < 0.0001) than in WT mice fed a low carbohydrate (1.9% sucrose) diet (Figure 1A). In 338 
contrast, GLP-2 receptor knockout mice demonstrated no differences in SGLT1 mRNA expression.  339 
The amount of SGLT1 mRNA in knockout mice maintained on either diet was identical to that in 340 
wild-type mice on the low carbohydrate diet, indicating that there is a constitutive pathway, 341 
independent of GLP-2 action that maintains a basal expression level of SGLT1, and an inducible 342 
pathway dependent on GLP-2. 343 
The abundance and activity of SGLT1 protein in brush border membrane vesicles (BBMV) isolated 344 
from proximal intestine were assessed by western blotting and Na+-dependent glucose uptake (Figure 345 
1B-C). In BBMV from WT mice on the high-carbohydrate diet, there was a 2.2-fold increase (P = 346 
0.0.300) in SGLT1 protein abundance compared to the low-carbohydrate diet, which correlated with 347 
a 2.7-fold increase (P = 0.0387) in the initial rate of Na+-dependent glucose transport into BBMV 348 
(Figures 1B and 1C) (Rates of Na+-dependent glucose transport were 150.2 ± 28.2 and 55.5 ± 8.0 349 
pmol s-1 (mg protein)-1 for two diet groups respectively); a similar increase in SGLT1 mRNA 350 
abundance and glucose transport was observed in BBMV isolated from the mid small intestine (data 351 
not shown). There was also a comparable increase in SGLT1 expression and activity when mice were 352 
maintained on low- or high-carbohydrate diets for one day, indicating that the increase in SGLT1 353 
occurs in the existing enterocytes. Conversely, GLP-2 receptor knockout mice had similar amounts 354 
of intestinal SGLT1 protein and Na+-dependent glucose transport when maintained on either the low- 355 
or high-carbohydrate diet. Thus, whereas wild-type mice are known to respond to increased dietary 356 
carbohydrates with enhanced SGLT1 expression (3,7), GLP-2 receptor knockout mice did not 357 
respond in this manner. 358 
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Immunohistochemistry showed that SGLT1 protein was expressed, irrespective of genotype, on the 359 
luminal membrane of entire villus enterocytes with no expression in the crypt; the intensity of 360 
labeling was higher in the intestine of WT mice maintained on a high carbohydrate diet (Figure S1).  361 
Morphometric analysis demonstrated that neither crypt-depth nor villus-height differed in the 362 
intestines of WT mice maintained on either a low- or a high-carbohydrate diet (Figure 2), confirming 363 
that the observed GLP-2 induced increase in SGLT1 expression is not due to the tropic effect of 364 
GLP-2. Moreover, specific activity of sucrase and maltase, two brush border membrane proteins, in 365 
the intestine of WT mice maintained either on low- or high-carbohydrate diet were unchanged (Table 366 
S3), indicating that the GLP-2 dependent SGLT1 regulatory pathway is distinct from the 367 
intestinotrophic effect of GLP-2; the latter influences villus height and the abundance of brush border 368 
membrane digestive and absorptive proteins (30).  369 
 370 
4.2 Expression of T1R2, T1R3 and GLP-2 in mouse enteroendocrine cells  371 
Having shown GLP-2 involvement in the pathway regulating SGLT1 expression in response to 372 
dietary sugars, we assessed the cellular location of T1R2-T1R3 and GLP-2 in mouse proximal 373 
intestine.  Enteroendocrine cells were identified by the presence of the enteroendocrine cell marker, 374 
chromogranin A. Triple immunohistochemistry demonstrated that T1R2, T1R3 and GLP-2 are co-375 
expressed in the same L-enteroendocrine cell (Figure 3). Similar T1R2-T1R3 co-expression was 376 
observed in the intestine of the glp2r-/- mice (Figure S2). Pre-incubation of GLP-2 primary antibody 377 
with the corresponding peptide antigen blocked the immunoreactive signal, indicating specificity of 378 
labeling (Figure 3). T1R2 and T1R3 antibody specificity has been previously validated (7,20,25,28). 379 
Approximately 30% of enteroendocrine cells contained GLP-2, with T1R3 and T1R2 being present 380 
in 16% and 10% of endocrine cells respectively. The cells that contained T1R2 also possessed GLP-2 381 
and T1R3. 382 
 383 
4.3 Glucose and sucralose, but not aspartame, elicit GLP-2 release from mouse small 384 
intestine  385 
Segments of mouse proximal small intestine were incubated with increasing concentrations of D-386 
glucose as described previously (25). Results demonstrated a dose-dependent increase in GLP-2 387 
secretion, with 50, 100 and 200 mM D-glucose eliciting 140 ± 14 pM (1.6-fold, P = 0.0369), 187 ± 13 388 
pM (2.2-fold, P = 0.0051) and 245 ± 20 pM (2.8-fold P =  0.0434) compared to control (86.5 ± 15.5 389 
pM) respectively (Figure 4A). To assess the potential effect of media osmolarity, intestinal tissues 390 
were also incubated with mannitol (10 – 200 mM); no GLP-2 secretion above that of the control was 391 
observed (Figure 4A). When intestinal tissues were pre-incubated with gurmarin (an inhibitor of 392 
mouse T1R3) (26), glucose-induced secretion of GLP-2 was abolished (P = 0.0062) (Figure 4B); 393 
gurmarin alone had no effect on GLP-2 secretion. In contrast, phloridzin, an inhibitor of SGLT1 had 394 
no effect on glucose-induced GLP-2 release ruling out the involvement of SGLT1 as a sensor (data 395 
not shown).   396 
To assess the effect of artificial sweeteners on GLP-2 release, mouse intestinal segments were 397 
incubated in media supplemented with either 10 mM sucralose or aspartame. Incubation with 398 
sucralose resulted in 1.5-fold (P = 0.0026) higher secretion of GLP-2 compared to untreated control; 399 
this was abolished when intestinal sections were pre-incubated with gurmarin (P = 0.0088) (Figure 400 
4C). Aspartame which does not activate mouse T1R2-T1R3 (31) did not induce GLP-2 secretion 401 
(Figure 4D). Tissue integrity was assessed by Hematoxylin-Eosin (H&E) staining and determination 402 
of lactate dehydrogenase as reported previously (23) (Figure S3). 403 
 404 
4.4 Electric field stimulation (EFS) of mouse small intestine enhanced SGLT1 expression  405 
In response to 20 min of EFS, there was a 2-fold (P = 0.0037) increase in SGLT1 mRNA levels (and 406 
remained the same after 30 min) compared to unstimulated tissue (Figure 5A). A similar increase in 407 
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SGLT1 protein abundance, 2.3-fold (P = 0.0461), was also observed in tissues stimulated for 20 min 408 
(Figures 5B and 5C). This increase in SGLT1 expression was abolished when the tissue was pre-409 
incubated with the neuronal sodium-channel blocker TTX (Figure 5A-C). TTX alone had no effect 410 
on SGLT1 expression in unstimulated tissue (data not shown).  411 
 412 
4.5 The effect of modulators of intracellular cAMP on SGLT1 expression in Caco-2 cells  413 
A widely used model cell line of intestinal absorptive enterocytes, Caco-2/TC7, was used to assess 414 
expression levels of SGLT1 in response to a number of agents known to increase intracellular cAMP. 415 
The time course of response to 8-Br-cAMP (a membrane permeable analogue of cAMP) was 416 
determined in order to establish the shortest time that elicits a significant increase in SGLT1 417 
expression. In response to 0.5 mM 8-Br-cAMP, steady-state levels of SGLT1 mRNA increased 2.3-418 
fold (P < 0.001) after 24 hours (Figure 5A-C).  419 
Having shown that electric field stimulation of enteric neurons resulted in enhanced expression of 420 
SGLT1, we tested several neuropeptides for their effect on SGLT1 mRNA abundance in Caco-2 421 
cells. The principal selection criteria were i) established stimulatory effect on cAMP accumulation ii) 422 
action via stimulatory GPCR (Gs) and iii) known expression in intestinal tissue. Accordingly, VIP, 423 
PACAP, CRH, CGRP and substance P were selected. Substance P, while acting principally via Gq, is 424 
reported to increase cAMP formation via Gs (32). Cells were exposed for 24 hours to a range of 425 
concentrations (10 nM – 1 µM) of neuropeptides. In response to 100 nM VIP, there was a 1.3-fold 426 
increase in SGLT1 mRNA abundance (P < 0.01) with a 2-fold increase observed at 1 µM (P < 427 
0.001); the latter a similar magnitude of response to that seen after exposure to 0.5 mM 8-Br-cAMP 428 
(Figures 6A and 6C). The effect of PACAP also increased with concentration, with a 1.8 fold 429 
increase in SGLT1 mRNA at 100 nM and a 2.2-fold increase at 1 µM (both P < 0.001) (Figures 6A 430 
and 6D).  When Caco-2 cells were incubated with 1 µM VIP and PACAP there was a 1.7- (P = 431 
0.0155) and 1.6-fold (P = 0.0236) increase in SGLT1 protein abundance a for VIP and PACAP 432 
respectively (Figure 6B). In contrast, CRH, CGRP and Substance P had no effect on SGLT1 mRNA 433 
and protein expression (Figure 6A and 6B).  434 
 435 
4.6 Vasoactive intestinal polypeptide receptor 1 (VPAC1) is expressed on the basolateral 436 
membrane of absorptive enterocytes 437 
Biological responses induced by VIP or PACAP are triggered by interaction with two receptors, 438 
VPAC1 and VPAC2, which are mainly coupled to the stimulatory G-protein, Gs, resulting in 439 
stimulation of cellular adenylate cyclase (33). Using PCR, we showed that Caco-2 cells express 440 
VPAC1 mRNA, but not VPAC2, while mouse small intestine possesses both VPAC1 and VPAC2 441 
mRNA (data not shown). By immunohistochemistry, we demonstrated that VPAC1 is expressed on 442 
the basolateral membrane of mouse absorptive enterocytes (Figures 7A and 7B); whereas no labeling 443 
for VPAC2 was observed on the plasma membrane of any intestinal epithelial cells (data not shown). 444 
Pre-incubation of the antibody with the immunizing peptide blocked the labeling, showing antibody 445 
specificity (Figure 7C).  446 
 447 
5 Discussion 448 
SGLT1 is expressed on the apical membrane of enterocytes, and is the major route for absorption of 449 
dietary glucose. Sensing of glucose by the sweet taste receptor, T1R2-T1R3, expressed in 450 
enteroendocrine L-cells, activates a pathway leading to upregulation of SGLT1 expression in 451 
neighboring absorptive enterocytes (7).  452 
In response to luminal glucose, L-enteroendocrine cells secrete the gut hormone, GLP-2 (34). L-cells 453 
have been identified throughout the intestinal tract, with the highest numbers observed in the distal 454 
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intestine (35). However, the proximal intestine has the greater density of GLP-2 receptor cells (36), 455 
and shows the largest response to pharmacological stimulation of the GLP-2 receptor (37,38). GLP-2 456 
is implicated in enhancing SGLT1 expression and intestinal glucose transport (8,9,10,11).  It exerts it 457 
effect by binding to its receptor (GLP-2R).  458 
Here, we show that knocking out the GLP-2 receptor abolishes the ability of mouse intestine to 459 
increase SGLT1 expression in response to increased dietary carbohydrate.  This supports our 460 
hypothesis that GLP-2 is part of the sugar-induced pathway in the intestinal mucosa that regulates 461 
SGLT1 expression.  462 
Immunohistochemistry on the intestinal tissues of WT and GLP2r-/- mice maintained on low or high 463 
carbohydrate diets demonstrated that in all cases, irrespective of genotype and diet, SGLT1 protein is 464 
expressed on the luminal membrane of entire villus enterocytes with no labeling in the crypt.  Thus, 465 
lack of response to low and high carbohydrate diet in GLP2r-/- is not due to altered profile of SGLT1 466 
protein expression along crypt-villus axis, but due to absence of receptor for GLP-2 required for this 467 
gut hormone to bind to, in order to exert its biological effect.   468 
It is now widely recognized that GLP-2 receptor is expressed in the submucosa and myenteric plexus 469 
and not in intestinal epithelial cells (17,18). The enteric neurons send most of their axonal projections 470 
to the muscle layers of intestine, while submucosal plexus neurons send the majority of their 471 
projections to sub-epithelial regions. The findings that GLP-2 receptor is expressed in the submucosa 472 
and myenteric plexus and not in intestinal epithelial cells rule out a direct paracrine effect of GLP-2 473 
on neighboring absorptive enterocytes and proposes a potential role for the enteric nervous system in 474 
the regulatory pathway underlying GLP-2 induced upregulation of SGLT1 expression. Neuronal 475 
action potential mostly depends on the function of voltage gated sodium channels which are 476 
specifically inhibited by TTX (39).  We show that pre-treatment of mouse intestinal tissue with TTX 477 
abolishes the upregulation of SGLT1 mRNA and protein in response to electric field stimulation, 478 
signifying the involvement of enteric nervous system in the regulatory process.  479 
Increased levels of intracellular cAMP in absorptive enterocytes lead to upregulation of SGLT1 480 
expression (12) demonstrating the involvement of this second messenger in the SGLT1 regulatory 481 
pathway. It has been shown that a number of cAMP-elevating agents increase SGLT1 expression at 482 
levels of mRNA, protein and function (5, 40) and that cAMP-induced post-transcriptional regulation 483 
of mRNA stability plays a major role in SGLT1 upregulation. 484 
Our experimental evidence suggests that T1R2-T1R3, expressed in enteroendocrine L-cells, detects 485 
luminal glucose concentrations. When above a threshold, glucose activates a signaling pathway 486 
involving T1R2-T1R3, the associated G-protein gustducin, and other signaling elements resulting in 487 
GLP-2 secretion. The binding of GLP-2 to its receptor on the submucosal plexus elicits a neuronal 488 
response (17) which is transmitted to sub-epithelial regions through axonal projections that are in 489 
close proximity to the basolateral membrane domain of absorptive enterocytes (41) evoking the 490 
release of VIP or PACAP. Binding of VIP and/or PACAP to its receptor, VPAC1, expressed on the 491 
basolateral membrane of absorptive enterocytes, enhances intracellular levels of cAMP, thereby 492 
increasing SGLT1 expression.  493 
It is noteworthy that VIP is released from the intestine in response to electric field stimulation (42) 494 
and that GLP-2 increases enteric neuronal expression of VIP in vivo (43). 495 
It has been shown that long term GLP-2 administration results in increased crypt-villus height (44, 496 
45) and that in the small intestine, insulin growth factor 1 (IGF-1),  (and likely other growth factors 497 
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such as ErbB ligands) is an essential mediator of the intestinotrophic action of GLP-2 (30,46,47). 498 
Assessing the intestinal tissues of WT and IGF-1 knockout mice (kindly provided by Drs. Brubaker 499 
and Dubé, University of Toronto) we demonstrated that there were no differences in the expression 500 
level of SGLT1 between WT and IGF-1 knockout mice when maintained on a high (61.8%) 501 
carbohydrate diet (data not shown), indicating that the GLP-2 dependent pathway underlying 502 
regulation of SGLT1 is distinct from GLP-2 induced intestinal growth.  503 
In the intestine of patients with type 2 diabetes, there is enhanced expression of SGLT1 mRNA, 504 
protein abundance and Na+-dependent D-glucose uptake (14). The increase is independent of the 505 
amount of dietary carbohydrate intake, blood glucose or insulin, and is likely to be due to 506 
deregulation of the pathway regulating expression of intestinal SGLT1 (14). The ability of the 507 
intestine to increase glucose absorption in diabetes further complicates the pathophysiology of this 508 
disease. The understanding of the regulatory pathway controlling SGLT1 expression allows 509 
identification of targets for controlling the capacity of the gut to absorb glucose. This has attendant 510 
promise for preventing and/or treating conditions such as malabsorption, diabetes and obesity. 511 
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11 Figure legends 666 
 667 
Figure. 1. SGLT1 expression in proximal small intestine of wild-type and Glp2r-/- mice in response to 668 
consumption of varied levels of dietary carbohydrate. Wild-type (WT) and Glp2 receptor knockout 669 
(Glp2r-/-) mice were fed low (L, □) or high (H, ■) carbohydrate diets as described in methods. (A) 670 
Steady state levels of SGLT1 mRNA abundance as determined by qPCR. (B left) SGLT1 protein 671 
abundance in brush-border membrane vesicles (BBMV) isolated from proximal small intestine 672 
measured by western blot analysis. (B right) Densitometric analysis of western blots of SGLT1 protein 673 
abundance normalized to that of β-actin. (C) SGLT1-mediated glucose uptake determined by Na+-674 
dependent D-[U14C] glucose uptake into same population of BBMV used in B, measured as pmol s-1 675 
(mg protein)-1. All values are expressed relative to SGLT1 expression in the proximal small intestine 676 
of wild-type mice on low-carbohydrate diets for 5 d, as means ± SEM. Data were generated in triplicate, 677 
with n = 6-8 animals in each group. Statistically significance determined by Student’s unpaired two-678 
tailed t test are indicated by * P < 0.05; *** P < 0.001. 679 
 680 
Figure 2. Villus height and crypt depth measurements in wild type and Glp2r-/- mice maintained on 681 
low- or high-CHO diets. (A) Representative light micrograms of small intestine of wild type and  682 
Glp2r-/- mice fed either a low carbohydrate (LCHO) or high-carbohydrate (HCHO) diet as described 683 
in the method section. Images represent 10X magnification. B) Morphometric analyses of villus height 684 
and crypt depths are shown as histograms, in µm ± SD. Low-CHO-fed wild type ( ), High-CHO-fed 685 
wild type ( ), Low-CHO-fed Glp2r-/- ( ), High-CHO-fed Glp2r-/- ( ); n = 4 per group. Statistically 686 
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significant results were determined using One-way ANOVA with Dunnett’s multiple comparison post-687 
test. 688 
 689 
Figure 3. Co-expression of T1R2, T1R3 and GLP-2 in wild-type mice small intestine. Representative 690 
image shows expression of T1R2 (red), T1R3 (blue) and GLP-2 (green) in serial sections of wild-type 691 
mice small intestine as determined by triple immunohistochemistry. The merged image (purple) shows 692 
co-localization of T1R2, T1R3 and GLP-2 in the same enteroendocrine cell. A typical control image 693 
showing that pre-incubation of GLP-2 primary antibody with the corresponding peptide antigen blocks 694 
the immunoreactive signal. Scale bar = 10 µm.   695 
 696 
Figure 4. Mouse small intestine secretes GLP-2 in response to glucose and sucralose but not aspartame. 697 
(A) Secretion levels of GLP-2 by mouse small intestinal tissue sections incubated at 37°C in media 698 
supplemented with increasing concentrations of glucose or mannitol. (B-D) Measurements of GLP-2 699 
release in media supplemented with either10 mM of (B) glucose (Glu), (C) sucralose (Suc), (D) 700 
aspartame (Asp), ± 5 µg/ml gurmarin (G); or untreated (Con); GLP-2 secretion was measured as 701 
described in Methods. Data are expressed as means ± SEM. (n = 9 per group), where P values are based 702 
on unpaired Student’s t-tests. * P < 0.05, ** P < 0.01 and *** P < 0.001. 703 
 704 
 705 
Figure 5. Effect of electric field stimulation on SGLT1 expression. Mouse intestinal loops were 706 
stimulated continuously for different periods of time, using frequency of 20 Hz, with 0.3 ms duration, 707 
1 ms delay and 50 V in the absence/presence of TTX or remained unstimulated as described in 708 
Methods. (A) SGLT1 mRNA abundance as assessed by qPCR, in unstimulated tissue (Con), stimulated 709 
tissue (20 min) or tissue stimulated for 20 min in the presence of the 10 µM tetrodotoxin (TTX). (B): 710 
Abundance of SGLT1 protein, determined by western blot analysis, in BBMV isolated from mouse 711 
small intestinal tissue that was either stimulated for 20 or 30 min (20 min & 30 min), in the presence 712 
of tetrodotoxin  (TTX), or left unstimulated (Con). (C): Densitometric analysis of western blots 713 
normalized to β-actin protein abundance (n = 5-9). Data are expressed as means ± SEM. P values are 714 
based on unpaired Student’s t-tests. * P < 0.05; ** P < 0.01. 715 
 716 
Figure 6. Effect of intracellular cAMP modulators on SGLT1 protein and mRNA expression in 717 
Caco-2/TC7 cells. Confluent Caco-2 cells were exposed to either 0.5 mM 8-Br-cAMP ( ), 1µM of 718 
each, VIP, PACAP, CRH, CGRP or Substance P, or maintained in untreated medium ( ). (A) 719 
Expression of SGLT1 mRNA, as determined by qPCR, in Caco-2 cells, n = 15. (B) Expression of 720 
SGLT1 protein abundance, as determined by western blotting, in PNM isolated from Caco-2 cells 721 
(upper panel).  Densitometric analysis of western blots of SGLT1 protein abundance was normalized 722 
to that of β-actin (lower panel), n = 3. (C & D) SGLT1 mRNA expression measured in response to 723 
graded concentrations (100 pM – 1 µM) of VIP (C) and PACAP (D), n = 15. Data are expressed as 724 
means ± SEM. P values are based on one-way ANOVA with Dunnett’s multiple comparison post-test. 725 
* P < 0.05, ** P < 0.01, *** P < 0.001. 726 
 727 
Figure 7. Localization of VIP/PACAP receptor in mouse small intestine. Typical immunofluorescent 728 
images showing expression of VPAC1 protein on the basolateral membrane of mouse intestinal 729 
enterocytes (A and B). No labeling was observed with omission of the primary antibody (C, control). 730 
VPAC2 protein was not expressed. BLM = Basolateral membrane. 731 
 732 
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